Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06524648

International Pilot Study for Dual Non-invasive Assesment of Embryo Development

Choosing the best embryo is one of the major challenges for achieving success in in vitro fertilization (IVF). Traditionally, embryo evaluation has been based on morphological quality (how the embryo looks like) and chromosomal status as diagnosed by a genetic testing. However, recently new techniques that do not require manipulation of the embryo have been developed and have shown promising results.

The goal of this observational study is, by combining two non-invasive techniques, to find out some parameters during embryo development which may be related with the embryo's chromosomic status. For that, infertile women planning to undergo an IVF/ICSI treatment with a recommended niPGT-A (non-invasive Preimplantation Genetic Testing for Aneuploidies) will be invited to join the study. The main question it aims to answer is:

* Can morphokinetics parameters correlate with embryo chromosomal status?

Participants will follow their previously programmed IVF/ICSI treatment and no additional visits/interventions will be required by their participation in the study. The obtained embryos will be cultured in a time-lapse system instead of in a conventional incubator, and niPGT-A will be performed. Following the standard practice, a deferred single embryo transfer (SET) will be performed according to the niPGT-A results. After the transfer, patients will be followed-up as usual.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–42 year

Sex eligibility

Female

Study type

Observational

Primary location

Kinderwunsch Institut Schenk, Dobl, Austria

Loading trial locations.

About this study

Embryo selection represents one of the major challenges for achieving success in in vitro fertilization (IVF) cycles. Traditionally, embryo evaluation has been based on morphological quality and chromosomal status as diagnosed by a genetic testing. However, recently new non-invasive techniques that do not require additional manipulation of the embryo have been developed and have shown promising results. One such technique is the time-lapse (TL) system imaging, which considers the embryo's development in relation to its rate of division and evolution (morphokinetics). Several algorithms have been developed to aid in the selection of embryos with the highest potential for implantation by collecting data on morphokinetic events during in vitro preimplantation development. Another non-invasive method is the analysis of the cell-free desoxyribonucleic acid (cfDNA) in the culture medium, considered as a non-invasive preimplantation genetic testing for aneuploidies (niPGT-A). Despite both techniques have shown promising results, each one has its limitations, and further research is necessary to identify synergies between them with the aim of finding a more powerful approach for embryo viability evaluation.

The combination of TL and niPGT-A might have the potential to improve the embryo evaluation and thus to improve the reproductive outcome rates in IVF treatments. Therefore, the aim of the present pilot study is to identify morphokinetic parameters during embryo development in a time-lapse system which may correlate with niPGT-A results.

Once the study is approved by the competent Research Ethics Committee of each center, the recruitment and selection of patients will follow. Every potential participant will be asked to sign the study informed consent. To comply with the study design and the proposed hypothesis, an estimated total number of 200 patients will be recruited.

This is a multicenter, international, competitive, observational, prospective cohort study in which infertile women scheduled for an IVF/ICSI treatment with medical recommendation of niPGT-A will have their embryos cultured in a time-lapse system instead of in a standard incubator. On day 6/7 of embryo development, the embryo's culture medium will be collected and analyzed by niPGT-A. A subsequent embryo transfer will be performed following the niPGT-A report recommendation and participants will be followed up as routine by their gynecologist. If a pregnancy is achieved, participants will be followed up until the 12th gestational week and, if possible, until the delivery. If pregnancy is not achieved, patients can perform as many SET/COS as they need during the study recruitment period.

Data exported from the medical records and source documents will be duly codified to protect the clinical and personal information of patients in accordance with the current legislation on data protection. This information will be exported to an internal database. An interim data analysis will be carried out once the 50% of the niPGT-A cycles (100 cycles) is reached. It will help us to assess the enrollment rate, protocol compliance and an early evaluation of the study objectives.

Patient´s participation will comprise an estimated total time of up to 11 months: 1 month for the COS cycle + 1 month for the ET cycle + ≤ 9 months for the follow-up period (≤12th gestational week and ≤ 40th gestational week, when applicable).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Study ICF signature.
  • Female age between 20 and 42 years (bot included).
  • IVF, ICSI or IVF/ICSI performed in fresh own or donated oocytes. Note: donor sperm is allowed.
  • niPGT-A cases with a deferred SET (of a day 6/7 vitrified blastocyst) for any medical indication.
  • Embryos cultured individually in a TL system from day 0/1 to day 6/7.

Exclusion criteria

  • Embryos with abnormal fertilization (different from 2PN). (Note: In case of no 2PN embryos, patients may repeat the COS cycle).
  • Female/couple with PGT-M and/or PGT-SR indication.
  • Assisted hatching and/or artificial collapse before media collection.
  • Known abnormal karyotype.
  • Pathologies or malformations affecting the uterine cavity (polyps, intramural myomas ≥ 4cm or submucosal, septum or hydrosalpinx) during the patient's participation. (Note: patients are allowed to participate if the pathology is previously operated at least 3 months before patient enrollment).
  • Any illness or medical condition that is unstable or which, according to medical criteria, may put at risk the patient's safety and her compliance in the study.

Treatment and study plan

niPGT-A

Diagnostic Test

Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.

Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).

Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active.

Primary outcomes

  1. Identification of embryo morphokinetic parameters which correlate with niPGT-A results

    Time frame: Up to 6/7 days

    Comparison of embryo morphokinetic parameters from the time-lapse (day 0 to day 6/7) with the niPGT-A results (informativity and ploidy)

Secondary outcomes

  1. Correlation between the implantation rate (IR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: Up to 4 weeks after the embryo transfer

    Analysis to determine the correlation between morphokinetic parameters and the IR, defined as the number of gestational sacs observed by vaginal ultrasound divided by the number of embryos transferred.

  2. Correlation between the clinical pregnancy rate (CPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: Up to 5-6 weeks after the embryo transfer

    Analysis to determine the correlation between morphokinetic parameters and the CPR, defined as the number of pregnancies with ultrasonographic visualization of one or more gestational sacs and/or fetal heartbeat, per embryo transfer.

  3. Correlation between the biochemical pregnancy rate (BPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: Around 2 weeks after the embryo transfer

    Analysis to determine the correlation between morphokinetic parameters and the BPR, defined as the number of pregnancies diagnosed only by β-hCG detection (≥25 mIU/ml) without a gestational sac visualized by vaginal ultrasound, per number of pregnancies.

  4. Correlation between the ectopic pregnancy rate (EPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: Up to 4-5 weeks after the embryo transfer

    Analysis to determine the correlation between morphokinetic parameters and EPR, defined as the number of pregnancies outside the uterine cavity, diagnosed clinically, hormonally, by ultrasound, surgical visualization or histopathology, per number of pregnancies.

  5. Correlation between the clinical miscarriage rate (CMR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: Over 12 gestational weeks

    Analysis to determine the correlation between morphokinetic parameters and the CMR, defined as the number of spontaneous pregnancy losses before the 12th gestational week, in which a gestational sac/s was previously observed and heartbeat detected, per number of pregnancies.

  6. Correlation between the ongoing pregnancy rate (OPR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: ≥12 gestational weeks

    Analysis to determine the correlation between morphokinetic parameters and the OPR, defined as the number of pregnancies of, at least,12 gestational weeks (at least one fetus with a discernible heartbeat diagnosed) achieved per each embryo transfer.

  7. Correlation between the Live Birth Rate (LBR) and embryo morphokinetic parameters in the niPGT-A guided single embryo transfer (SET)

    Time frame: 40 gestational weeks

    Analysis to determine the correlation between morphokinetic parameters and the LBR, defined as the number of live births per embryo transfer. Live birth is defined as the complete expulsion or extraction from a woman of a product of conception after 22 weeks of gestation, which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached.

  8. Identification of morphokinetic parameters which might predict the optimal time for media collection.

    Time frame: Up to 6/7 days of embryo development

    Comparison of niPGT-A informativity results with morphokinetic parameters

  9. To explore the relationship between niPGT-A results and morphokinetics with the type of ovarian stimulation and induction, the patient's intertility history and embryo quality

    Time frame: Over 3-4 weeks

    Multivariant analysis to determine how the relationship between niPGT-A results and morphokinetics is affected by ART/patient variables: type of ovarian stimulation and induction, the patient's intertility history (previous miscarriages, known infertility causes, previous implantation failures), and embryo quality (determined by standard morphology evaluation).

  10. Identification of the correlation between morphokinetic parameters and spent blastocyst media contamination

    Time frame: Up to 6/7 days of embryo development

    Correlate morphokinetic parameters with the presence of maternal and/or external DNA in the culture media for niPGT-A

  11. Comparison of the products of conception (POC) results with the niPGT-A results

    Time frame: Up to 12 gestational weeks

    Correlate the niPGT-A results with the POC results

  12. To study the relathionship among the morphokinetics, niPGT-A and the patient's body mass index (BMI)

    Time frame: Up to 6/7 days

    To anlyse the patient's BMI influence on the correlation between morphokinetics and niPGT-A, only when own oocytes are used.

Other outcomes

  1. To evaluate the relathionship of the cell-free DNA (cfDNA) concentration of the spent blastocyst media (SBM) with morphokinetic parameters and/or niPGT-A

    Time frame: Up to 6/7 days of embryo development

    To assess the cfDNA concentration in a 20% of the SBMs and evaluate its correlation with morphokinetic parameters and/or niPGT-A

Study contacts

Contact information is provided by the study sponsor or research team.

Carlos Gomez, BSc MSc

CONTACT

[email protected]

+34963905310

Ianae Ceschin, MSc

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Igenomix

Industry

Registry information

Official study title

A Prospective, Multicenter, Observational Pilot Study to Evaluate the Combination of niPGT-A and Morphokinetics for the Non-invasive Assessment of Embryo Development

Acronym: PANDORA

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jul 29, 2024
Registry last updated
Aug 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.